Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

p53 Pathway dysfunction in primary childhood ependymomas.

Nathalie Gaspar1, Jacques Grill, Birgit Geoerger

  • 1Pharmacology and New Treatments in Cancer UPRES EA 3535, Institut Gustave Roussy, Villejuif, France.

Pediatric Blood & Cancer
|August 9, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spatial transcriptomic atlas of aggressive osteosarcomas reveals shared immune landscape and targetable surface markers.

Nature communications·2026
Same author

Language as an Eligibility Criterion in Pediatric Study Protocols Conducted in Europe (2007-2024) Reported in the ClinicalTrials.gov Database.

Pharmaceutical medicine·2026
Same author

Paediatric Therapeutic Development Workshop on rhabdomyosarcoma.

British journal of cancer·2026
Same author

Eligibility criteria in pediatric oncology phase I and II clinical trials: Analysis and recommendations for standardization from the Innovative Therapies for Children and Adolescents with Cancer (ITCC) Consortium.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Co-targeting CDK4/6 and MEK reverses mesenchymal transition in therapy-refractory BRAF-altered pediatric high-grade glioma.

Journal of experimental & clinical cancer research : CR·2026
Same author

Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial.

Nature medicine·2026
Same journal

Comment on: "The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience"-The Evolving Role of the BIT Regimen.

Pediatric blood & cancer·2026
Same journal

Extramedullary Intradural Spinal Tumor in an Infant With Neurocutaneous Melanosis.

Pediatric blood & cancer·2026
Same journal

The Role of Hematopoietic Cell Transplantation in Ataxia-Telangiectasia.

Pediatric blood & cancer·2026
Same journal

Pediatric T-Lymphoblastic Lymphoma With T(9;17) and MIR142HG::NOTCH1 Fusion Successfully Treated by Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission.

Pediatric blood & cancer·2026
Same journal

Reply to: Comment on: Investigating Biomarkers for Inborn Errors of Immunity in a Prospective Study of Patients With Autoimmune Cytopenia.

Pediatric blood & cancer·2026
Same journal

Comment on: Investigating Biomarkers for Inborn Errors of Immunity in a Prospective Study of Patients With Autoimmune Cytopenia.

Pediatric blood & cancer·2026
See all related articles

Childhood ependymoma treatment is challenging. This study found that altered p53-mediated growth arrest, not gene mutations, may contribute to radio-resistance in these pediatric brain tumors.

Area of Science:

  • Pediatric Oncology
  • Cancer Biology
  • Molecular Therapeutics

Background:

  • Childhood ependymoma presents significant therapeutic challenges.
  • The role of p53 pathway integrity in ependymoma radio-resistance is not fully understood.

Purpose of the Study:

  • To investigate the p53 pathway status in childhood ependymomas.
  • To determine the functional impact of p53 on response to radiation therapy in ependymoma models.

Main Methods:

  • Analysis of p53 pathway components (TP53, MDM2, p14ARF, PAX5) in primary ependymomas and xenografts.
  • Functional assays including yeast-based functional assay, RT-PCR, Western blot, and immunohistochemistry.
  • Evaluation of p53-mediated DNA damage response to irradiation in ependymoma xenograft models (IGREP37, IGREP83) using Western blot and flow cytometry.

Related Experiment Videos

Main Results:

  • No TP53, MDM2, p14ARF, or PAX5 gene abnormalities were found in the tested ependymoma samples.
  • Altered p53-induced p21-mediated G1 growth arrest was observed in the IGREP37 xenograft model post-irradiation.
  • While IGREP37 showed moderate sensitivity to radiation, the p53-functional IGREP83 model exhibited significant tumor growth delays and regressions.

Conclusions:

  • Functional alterations in p53-mediated growth arrest, rather than genetic mutations, may contribute to radio-resistance in childhood ependymomas.
  • Further investigation into p53 pathway dysregulation is warranted for developing improved therapeutic strategies.